ArticleBMC cancer2015
c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 53 citations in OpenAlex.
- A network toxicology and machine learning approach to uncover the molecular machinery of bisphenol A-induced colorectal cancer.Scientific reports · 2026Article
- C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Longitudinal plasma proteomics identifies diagnostic and response-associated inflammatory and immune biomarkers in psoriasis following secukinumab therapy.Frontiers in immunology · 2026Article
- Survivin expression is associated with lymph node metastasis and short survival in patients with colorectal adenocarcinoma.International journal of clinical and experimental pathology · 2024Article
- Expression pattern, prognostic value and potential microRNA silencing of FZD8 in breast cancer.Oncology letters · 2023Article
- Clinical significance of galectin-3 expression in urinary bladder carcinoma.The Journal of international medical research · 2023Article
- c-Met-TargetingInternational journal of nanomedicine · 2023Article
- Strong prognostic value of SLAMF7 protein expression in patients with lymph node-positive breast cancer.Oncology letters · 2022Article
- Cyclooxygenase-2 immunohistochemical expression is associated with worse prognosis in breast cancer: Retrospective study and literature review.Saudi medical journal · 2022Review
- c-MET immunohistochemical expression in sporadic and inflammatory bowel disease associated lesions.World journal of gastroenterology · 2022Article
- Leptin expression is substantially correlated with prognosis of urinary bladder carcinoma.The Libyan journal of medicine · 2021Article
- Prognostic value of E-Cadherin and its tumor suppressor role in Saudi women with advanced epithelial ovarian cancer.The Libyan journal of medicine · 2021Article
- Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer.Journal of gastrointestinal oncology · 2021Article
- Vimentin immunoexpression is associated with higher tumor grade, metastasis, and shorter survival in colorectal cancer.International journal of clinical and experimental pathology · 2020Article
- Overexpression of SIRT1 in urothelial carcinoma of the urinary bladder is associated with local recurrence and poor survival.Saudi medical journal · 2019Article
- Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis.Journal of biochemical and molecular toxicology · 2019Article
- Immunhistochemical expression of GLUT1 is associated with low grade and low stage of urinary bladder cancer.International journal of clinical and experimental pathology · 2019Article
- Fascin expression in urinary bladder urothelial carcinoma correlates with unfavourable prognosis.International journal of clinical and experimental pathology · 2019Article
- Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis.Analytical cellular pathology (Amsterdam) · 2019Article
- Long Noncoding RNA GAPLINC Promotes Cells Migration and Invasion in Colorectal Cancer Cell by Regulating miR-34a/c-MET Signal Pathway.Digestive diseases and sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreased mesenchymal-epithelial transition factor gene (c-MET) expression in several human malignancies is related to increased tumour progression. The aim of the present study is to explore the relationship between immunohistochemical expression of c-MET in colorectal carcinoma (CRC) and the clinicopathological characteristics and follow up data, to compare the expression of c-MET in primary CRC and its metastasis in lymph nodes and to test its validity as independent prognostic factor.
methodsHundred and thirty-five archival CRC and nodal metastases samples were collected from King Abdulaziz University Hospital, Saudi Arabia. Tissue microarrays were constructed and immunohistochemistry was done to detected c-MET protein expression. Appropriate statistical analysis was performed.
resultsHigh c-MET immunostaining was significantly associated with tumour size larger than 5 cm (p < 0.003) and in left colon subsite (p < 0.05). There was no significant correlation between c-MET protein expression and age, sex, degree of differentiation, tumour invasion, presence of nodal metastasis, lymphovascular invasion, status of surgical resection margin, or presence of distant metastasis. Furthermore, no association between c-MET protein expression and disease free survival. High protein expression of c-MET is associated with the incidence of local disease recurrence (p < 0.012).
conclusionc-MET is a new promising target that may help in understanding the pathogenesis of CRC, and to be used as independent prognostic biomarker to predict local disease recurrence in CRC. Further molecular in vitro and in vivo studies are required to pursue c-MET as potential molecular marker of metastases and test the possibility of its incorporation as a new targeted therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.